ClinicalTrials.gov
public full text
Public Domain
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
This study is designed to explore the efficacy and safety of anlotinib combined with benmelstobart and AG (nab-paclitaxel and gemcitabine) as first-line treatment compared with AG (nab-paclitaxel and gemcitabine) in metastatic pancreatic cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer#813592
- Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer#1114609
- A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC#1095949
- Stromal TARgeting for PAncreatic Cancer (STAR_PAC)#1138704
- Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer#837502
Record · ID 905259
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive